Summit Securities Group’s Maravai LifeSciences MRVI Stock Holding History

Summit Securities Group’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$27.3K	Buy	+3,563	New	+$24.6K	﹤0.01%	668
2025 Q4	–	Sell	-969	Closed	-$2.78K	–	1162
2025 Q3	$2.78K	Sell	969 -27,971	-97%	-$71.4K	﹤0.01%	943
2025 Q2	$69.7K	Buy	28,940 +24,713	+585%	+$51.9K	0.01%	430
2025 Q1	$9.34K	Buy	+4,227	New	+$16.7K	﹤0.01%	554
2024 Q4	–	Sell	-3,000	Closed	-$25K	–	810
2024 Q3	$25K	Buy	+3,000	New	+$25.9K	0.01%	315
2024 Q1	–	Sell	-2,000	Closed	-$13K	–	747
2023 Q4	$13K	Hold	2,000	–	–	﹤0.01%	505
2023 Q3	$20K	Sell	2,000 -1,000	-33%	-$11K	﹤0.01%	364
2023 Q2	$37K	Buy	+3,000	New	+$40.5K	﹤0.01%	478

Other funds holding MRVI

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

General American Investors New York $1.71B AUM 30.1% 1-Year Est. Return

Royce & Associates New York $11B AUM 39.4% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Monaco Asset Management Monaco $818M AUM 32.61% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Summit Securities Group's MRVI Position: Q3 2026 in Review

Summit Securities Group opened a new position in Maravai LifeSciences (MRVI) in Q3 2026: 3,563 shares worth $27.3K. The stake represents ﹤0.01% of the portfolio and ranks #668 among its holdings. This is a return to the name: Summit Securities Group previously reported a position in MRVI as recently as Q3 2025.

Summit Securities Group first reported a position in MRVI in Q2 2023 and has held it in 8 quarters since. The position peaked at $69.7K in Q2 2025. 70 funds tracked by Wall St. Rank hold MRVI as of Q3 2026.

Summit Securities Group held 3,563 shares of Maravai LifeSciences worth $27.3K as of Q3 2026.
Maravai LifeSciences was a new Summit Securities Group position in Q3 2026.
Maravai LifeSciences made up ﹤0.01% of Summit Securities Group's portfolio in Q3 2026, its #668 holding.
Summit Securities Group first reported a position in Maravai LifeSciences in Q2 2023 and has held it in 8 quarters since.
Summit Securities Group's Maravai LifeSciences position peaked at $69.7K in Q2 2025.
70 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q3 2026.

Based on Summit Securities Group's 13F filing for Q3 2026, filed 5 Nov 2026.